Mullerian adenosarcoma of the uterine corpus associated with tamoxifen therapy: A report of six cases and a review of tamoxifen-associated endometrial lesions

International Journal of Gynecological Pathology

Volumn 15, Issue 3, 1996, Pages 222-229

  Clement, Philip B ^a,c   Oliva, Esther ^b   Young, Robert H ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c VANCOUVER HOSPITAL AND HEALTH SCIENCES CENTRE   (Canada)

Author keywords

Adenosarcoma; Estrogen; Tamoxifen; Uterus

Indexed keywords

CONJUGATED ESTROGEN; MEDROXYPROGESTERONE ACETATE; TAMOXIFEN;

ADENOSARCOMA; ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RISK; CLINICAL ARTICLE; DRUG INDUCED DISEASE; FEMALE; GYNECOLOGIC CANCER; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; UTERUS CARCINOMA;

EID: 0029969963     PISSN: 02771691     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004347-199607000-00006     Document Type: Article

References (59)

1. Hardell L. Tamoxifen as risk factor for carcinoma of corpus uteri [Letter]. Lancet 1988;2:563.
2. Fornander T, Rutqvist LE, Cedermark B, et al. Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet 1989;1:117-20.
3. Neven P, De Muylder X, Van Belle Y, Vanderick G, De Muylder E. Tamoxifen and the uterus and endometrium [Letter]. Lancet 1989;1:375.
4. Nuovo MA, Nuovo GJ, McCaffrey RM, Levine RU, Barron B, Winkler B. Endometrial polyps in postmenopausal patients receiving tamoxifen. Int J Gynecol Pathol 1989;8:125-31.
5. Stewart HJ, Knight GM. Tamoxifen and the uterus and endometrium [Letter]. Lancet 1989;1:375-6.
6. Atlante G, Pozzi M, Vincenzoni C, Vocaturo G. Four case reports presenting new acquisitions on the association between breast and endometrial carcinoma. Gynecol Oncol 1990;37:378-80.
7. Malfetano JH. Tamoxifen-associated endometrial carcinoma in postmenopausal breast cancer patients. Gynecol Oncol 1990;39:82-4.
8. Mathew A, Chabon AB, Kabakow B, Drucker M, Hirschman RJ. Endometrial carcinoma in five patients with breast cancer on tamoxifen therapy. NY State J Med 1990;90:207-8.
9. Andersson M, Storm HH, Mouridsen HT. Incidence of new primary cancers after adjuvant tamoxifen therapy and radiotherapy for early breast cancer. JNCI 1991;83:1013-7.
10. De Muylder R, Neven P, De Somer M, Van Belle Y, Vanderick G, De Muylder E. Endometrial lesions in patients undergoing tamoxifen therapy. Int J Gynecol Obstet 1991;36:127-30.
11. Deligdisch L, Cohen CJ, Dottino P. Tamoxifen therapy and endometrial neoplasia [Abstract]. Eur J Cancer 1991;27 (suppl 2):127.
12. Fornander T, Rutqvist LE, Wilking N. Effects of tamoxifen on the female genital tract. Ann NY Acad Sci 1991;633:469-76.
13. Gal D, Kopel S, Bashevkin M, Lebowicz J, Lev R, Tancer ML. Oncogenic potential of tamoxifen on endometria of postmenopausal women with breast cancer - preliminary report. Gynecol Oncol 1991;42:120-3.
14. Spinelli G, Bardazzi N, Citernesi A, Fontanrosa M, Curiel P. Endometrial carcinoma in tamoxifen-treated breast cancer patients. J Chemother 1991;3:267-70.
15. Corley D, Rowe J, Curtis MT, Hogan WM, Noumoff JS, LiVolsi VA. Postmenopausal bleeding from unusual endometrial polyps in women on chronic tamoxifen therapy. Obstet Gynecol 1992;79:111-6.
16. Deprest J, Neven P, Ide P. An unusual type of endometrial cancer, related to tamoxifen? Eur J Obstet Gynecol Reprod Biol 1992;46:147-50.
17. Segna RA, Dottino PR, Deligdisch L, Cohen CJ. Tamoxifen and endometrial cancer. Mt Sinai J Med 1992;59:416-8.
18. Wolf DM, Jordan VC. Gynecologic complications associated with long-term adjuvant tamoxifen therapy for breast cancer. Gynecol Oncol 1992;45:118-28.
19. Cohen I, Rosen DJD, Shapira J, et al. Endometrial changes in postmenopausal women treated with tamoxifen for breast cancer. Br J Obstet Gynaecol 1993;100:567-70.
20. Fornander T, Hellstrom A, Moberger B. Descriptive clinicopathologic study of 17 patients with endometrial cancer during or after adjuvant tamoxifen in early breast cancer. JNCI 1993;85:1850-5.
21. Lahti E, Blanco G, Kauppila A, Apaja-Sarkkinen M, Taskinen PJ, Laatikainen T. Endometrial changes in postmenopausal breast cancer patients receiving tamoxifen. Obstet Gynecol 1993;81:660-4.
22. Magriples U, Naftolin F, Schwartz PR, Carcangiu ML. High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients. J Clin Oncol 1993;11:485-90.
23. Seoud MA, Johnson J, Weed JC Jr. Gynecologic tumors in tamoxifen-treated women with breast cancer. Obstet Gynecol 1993;82:165-9.
24. Ugwumadu AHN, Bower D, Ho PK. Tamoxifen induced adenomyosis and adenomyomatous endometrial polyp. Br J Obstet Gynaecol 1993;100:386-92.
25. Barakat RR, Wong G, Curtin JP, Vlamis V, Hoskins WJ. Tamoxifen use in breast cancer patients who subsequently develop corpus cancer is not associated with a higher incidence of adverse histologic features. Gynecol Oncol 1994;55:164-8.
26. Berezowsky J, Chalvardjian A, Murray D. Iatrogenic endometrial megapolyps in women with breast carcinoma. Obstet Gynecol 1994;84:727-30.
27. Cohen I, Rosen DJD, Shapira J, et al. Endometrial changes with tamoxifen: comparison between tamoxifen-treated and nontreated asymptomatic, postmenopausal breast cancer patients. Gynecol Oncol 1994;52:185-90.
28. Cohen I, Tepper R, Rosen DJD, et al. Continuous tamoxifen treatment in asymptomatic, postmenopausal breast cancer patients does not cause aggravation of endometrial pathologies. Gynecol Oncol 1994;55:138-43.
29. Fisher B, Costantino JP, Redmond CK, et al. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. JNCI 1994;86:527-37.
30. Ingle JN. Tamoxifen and endometrial cancer: new challenges for an "old" drug. Gynecol Oncol 1994;55:161-3.
31. Ismail SM. Pathology of endometrium treated with tamoxifen. J Clin Pathol 1994;47:827-33.
32. Kedar RP, Bourne TH, Powles TJ, et al. Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomized breast cancer prevention trial. Lancet 1994;343:1318-21.
33. Moberger B, Fornander T, Hellstrom A-C. DNA-content in endometrial carcinoma of tamoxifen-treated breast cancer patients. Int J Gynecol Cancer 1994;4:131-4.
34. Suva EG, Tornos CS, Follen-Mitchell M. Malignant neoplasms of the uterine corpus in patients with breast carcinoma: the effects of tamoxifen. Int J Gynecol Oncol 1994;248-58.
35. Sismondi P, Biglia N, Volpi E, Giai M, De Grandis T. Tamoxifen and endometrial cancer. Ann NY Acad Sci 1994;734:310-21.
36. van Leeuwen FE, Benraadt J, Coebergh JWW, et al. Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet 1994;343:448-52.
37. Cohen I, Altaras MM, Shapira J, et al. Time-dependent effect of tamoxifen therapy on endometrial pathologies in asymptomatic postmenopausal breast cancer patients. Int J Gynecol Pathol 1996;15:152-7.
38. Dallenbach-Hellweg G, Hahn U. Mucinous and clear cell adenocarcinomas of the endometrium in patients receiving antiestrogens (tamoxifen) and gestagens. Int J Gynecol Pathol 1995;14:7-15.
39. Folk JJ, Mazur MT, Eddy GL, Musa AG. Secretory endometrial adenocarcinoma in a patient on tamoxifen for breast cancer: a report of a case. Gynecol Oncol 1995;58:133-5.
40. Robinson DC, Bloss JD, Schiano MA. A retrospective study of tamoxifen and endometrial cancer in breast cancer patients. Gynecol Oncol 1995;59:186-90.
41. Bocklage T, Lee KR, Belinson JL. Uterine mullerian adenosarcoma following adenomyoma in a woman on tamoxifen therapy. Gynecol Oncol 1992;44:104-9.
42. Clement PB, Scully RE. Mullerian adenosarcoma of the uterus. A clinicopathological analysis of 100 cases with a review of the literature. Hum Pathol 1990;21:363-81.
43. Cohen I, Beyth Y, Tepper R, et al. Adenomyosis in postmenopausal breast cancer patients treated with tamoxifen: a new entity? Gynecol Oncol 1995;58:86-91.
44. Ford MRW, Turner MJ, Wood C, Soutter WP. Endometriosis developing during tamoxifen therapy. Am J Obstet Gynecol 1988;158:1119.
45. Mor-Yosef S, Shushan A, Uziely B, Lewin A, Peretz T. The effect of prolonged tamoxifen administration on the endomterium and ovaries of women with breast cancer [Abstract]. Int J Gynecol Cancer 1995;5(suppl 1):23.
46. Altaras MM, Aviram R, Cohen I, Cordoba M, Yarkoni S, Beyth Y. Role of prolonged stimulation of tamoxifen therapy in the etiology of endometrial sarcomas. Gynecol Oncol 1993;49:255-8.
47. Clarke MR. Uterine malignant mixed mullerian tumor in a patient on long-term tamoxifen therapy for breast cancer. Gynecol Oncol 1993;51:311-415.
48. Evans MJ, Langlois NEI, Kitchener HC, Miller ID. Is there as association between long-term tamoxifen treatment and the development of carcinosarcoma (malignant mixed mullerian tumor) of the uterus? Int J Gynecol Cancer 1995;5:310-3.
49. Sasco AJ, Raffi F, Satge D, Goburdhun J, Fallouh B, Leduc B. Endometrial mullerian carcinosarcoma after cessation of tamoxifen therapy for breast cancer. Int J Gynecol Obstet 1995;48:307-10.
50. Gillett D. Leiomyosarcoma of the uterus in a women taking adjuvant tamoxifen therapy [Letter]. Med J Aust 1995;163:160-1.
51. Beer TW, Buchanan R, Buckley CH. Uterine stromal sarcoma following tamoxifen treatment [Letter]. J Clin Pathol 1995;48:596.
52. Press MF, Scully RE. Endometrial "sarcomas" complicating ovarian thecoma, polycystic overian disease and estrogen therapy. Gynecol Oncol 1985;21:135-54.
53. Altaras MM, Jaffe R, Cohen I, Gruber A, Yanai-lnbar I, Bernheim J. Role of prolonged excessive estrogen stimulation in the pathogenesis of endometrial sarcomas: two cases and a review of the literature. Gynecol Oncol 1990;38:273-7.
54. Clement PB, Young RH. Atypical polypoid adenomyoma of the uterus associated with Turner's syndrome. A report of three cases, including a review of "estrogen-associated" endometrial neoplasms and neoplasms associated with Turner's syndrome. Int J Gynecol Pathol 1987;6:104-13.
55. Press ME, Greene GL. An immunocytochemical method for demonstrating estrogen receptor in human uterus using monoclonal antibodies to human estrophilin. Lab Invest 1984;50:480-6.
56. Press ME, Nousek-Goebl N, King WJ, Herbst AL, Greene GL. Immunocytochemical assessment of estrogen receptor distribution in the human endometrium throughout the menstrual cycle. Lab Invest 1984;51:495-503.
57. Soper JT, McCarty KS Jr, Hinshaw W, Creasman WT, McCarty KS Sr, Clarke-Pearson DL. Cytoplasmic estrogen and progesterone receptor content of uterine sarcomas. Am J Obstet Gynecol 1984;150:342-8.
58. Sabini G, Chumas JC, Mann WJ. Steroid hormone receptors in endometrial stromal sarcomas. A biochemical and immunohistochemical study. Am J Clin Pathol 1992;97:381-6.
59. Chumas JC, Mann WJ, Tseng L. Malignant mixed mullerian tumor of the endometrium in a young woman with polycystic ovaries. Cancer 1983;52:1478-81.